Spravato 2023 Sales in the US
In 2023, Spravato generated $561 million in net sales in the United States [1]. This represents a 23% increase compared to the previous year [1].
How is Spravato Used?
Spravato is a prescription nasal spray medication used to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior [2]. It is administered under the supervision of a healthcare provider in a certified medical office or clinic, and patients must be monitored for at least two hours after administration [3].
What are the Side Effects of Spravato?
Common side effects of Spravato can include dissociation, dizziness, nausea, sedation, vertigo, decreased blood pressure, and harmful effects on the brain [3]. Due to the risk of dissociation and sedation, Spravato is only available through a restricted distribution system called the Spravato REMS (Risk Evaluation and Mitigation Strategy) [3].
When Does Spravato's Patent Expire?
Information on Spravato's patent expiration is not publicly available in the provided context. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceuticals.
Who Manufactures Spravato?
Spravato is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [4].
What is Spravato's Mechanism of Action?
Spravato is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor [2]. Its exact mechanism in treating depression is not fully understood, but it is believed to increase synaptic plasticity and connectivity in brain regions involved in mood regulation [2].
What are the Alternatives to Spravato?
For treatment-resistant depression, alternatives include other antidepressant medications, psychotherapy, and electroconvulsive therapy (ECT) [5]. For depressive symptoms in MDD with acute suicidal ideation or behavior, immediate management may involve hospitalization and other psychiatric interventions [5].
What is the Cost of Spravato?
The cost of Spravato can vary based on insurance coverage and pharmacy. Patients should consult with their healthcare provider and insurance provider for specific cost information.
---
Sources
1. Janssen Pharmaceutical Companies of Johnson & Johnson. (2024). Janssen Reports 2023 Fourth Quarter and Full Year Results. https://www.janssen.com/janssen-reports-2023-fourth-quarter-and-full-year-results
2. U.S. Food & Drug Administration. (n.d.). SPRAVATO (esketamine) nasal spray. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/spravato-esketamine-nasal-spray
3. Janssen Pharmaceuticals. (n.d.). SPRAVATO® (esketamine) nasal spray Prescribing Information. https://www.janssen.com/sites/default/files/spravatoprescribinginformation.pdf
4. DrugPatentWatch.com. (n.d.). Spravato Patent and Exclusivity. https://drugpatentwatch.com/p/spravato
5. National Institute of Mental Health. (n.d.). Major Depression. https://www.nimh.nih.gov/health/topics/depression